Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBOETTIGER, David C.
dc.contributor.authorESCUDER, Maria Mercedes
dc.contributor.authorLAW, Matthew G.
dc.contributor.authorVELOSO, Valdilea
dc.contributor.authorSOUZA, Rosa A.
dc.contributor.authorIKEDA, Maria L. R.
dc.contributor.authorALENCASTRO, Paulo R. de
dc.contributor.authorTUPINAMBAS, Unai
dc.contributor.authorBRITES, Carlos
dc.contributor.authorGRINSZTEJN, Beatriz
dc.contributor.authorGGOMES, Jackeline O.
dc.contributor.authorRIBEIRO, Sayonara
dc.contributor.authorMCGOWAN, Catherine C.
dc.contributor.authorJAYATHILAKE, Karu
dc.contributor.authorCASTILHO, Jessica L.
dc.contributor.authorGRANGEIRO, Alexandre
dc.identifier.citationTROPICAL MEDICINE & INTERNATIONAL HEALTH, v.25, n.7, p.886-896, 2020
dc.description.abstractObjectives There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil. Methods Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014. Results Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9-4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR] 6.4 for >= 55 years vs. <35 years, 95% CI: 2.5-16.3, P < 0.01), black race (aHR 1.8 vs. white race, 95% CI: 1.0-3.1, P = 0.04), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4-6.2, P < 0.01), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0-3.1, P = 0.04), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0-14.6, P < 0.01), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2-5.0, P = 0.02) and low nadir CD4 cell count (aHR 1.8 for 100-250 cells/mm(3) vs. >250 cells/mm(3), 95% CI: 1.0-3.2, P = 0.05). The rate of death was 16.6 (95% CI: 15.1-18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1-2.7, P = 0.01). Conclusions Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.eng
dc.description.sponsorshipBrazilian National Council for Scientific & Technological Development
dc.description.sponsorshipBrazilian National Ministry of Health
dc.description.sponsorshipPan American Health Organization
dc.description.sponsorshipU.S. National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23AI1120875, P30AI110527]
dc.description.sponsorshipNIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01AI069923]
dc.description.sponsorshipEunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
dc.description.sponsorshipNational Cancer Institute (NCI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
dc.description.sponsorshipNational Institute Of Allergy And Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
dc.description.sponsorshipNational Institute Of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)
dc.description.sponsorshipOffice Of The Director, National Institutes Of Health (OD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA
dc.relation.ispartofTropical Medicine & International Health
dc.subjectcardiovascular diseaseeng
dc.subjectantiretroviral therapyeng
dc.subject.otheracute myocardial-infarctioneng
dc.subject.otherlong-term survivaleng
dc.subject.othernational-health surveyeng
dc.subject.otherabacavir useeng
dc.subject.otherantiretroviral therapieseng
dc.subject.otherincreased riskeng
dc.titleCardiovascular disease among people living with HIV in Brazileng
dc.rights.holderCopyright WILEYeng
dc.contributor.groupauthorHIV-Brazil Cohort Study
dc.subject.wosPublic, Environmental & Occupational Healtheng
dc.subject.wosTropical Medicineeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, David C.:Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94143 USA; Univ New South Wales, Kirby Inst, Sydney, NSW, Australia, Maria Mercedes:Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil, Matthew G.:Univ New South Wales, Kirby Inst, Sydney, NSW, Australia, Valdilea:Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil, Rosa A.:AIDS Reference & Training Ctr, Sao Paulo State Dept Hlth, Sao Paulo, Brazil, Maria L. R.:Univ Vale Rio dos Sinos, Sch Hlth, Porto Alegre, RS, Brazil, Paulo R. de:Hosp Sanatorio Partenon, Rio Grande Sul State Dept Hlth, Care & Treatment Clin, Porto Alegre, RS, Brazil, Unai:Univ Fed Minas Gerais, Med Sch, Belo Horizonte, MG, Brazil, Carlos:Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil, Beatriz:Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil, Jackeline O.:Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil, Sayonara:Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil, Catherine C.:Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA, Karu:Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA, Jessica L.:Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA
hcfmusp.relation.referenceBedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269eng
hcfmusp.relation.referenceBijker R, 2019, HIV MED, V20, P183, DOI 10.1111/hiv.12687eng
hcfmusp.relation.referenceBronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253eng
hcfmusp.relation.referenceBrothers CH, 2009, JAIDS-J ACQ IMM DEF, V51, P20, DOI 10.1097/QAI.0b013e31819ff0e6eng
hcfmusp.relation.referenceBrouwer ES, 2014, EPIDEMIOLOGY, V25, P406, DOI 10.1097/EDE.0000000000000041eng
hcfmusp.relation.referenceCastilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233eng
hcfmusp.relation.referenceChoi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16eng
hcfmusp.relation.referenceCruciani M, 2011, AIDS, V25, P1993, DOI 10.1097/QAD.0b013e328349c6eeeng
hcfmusp.relation.referenceDesai M, 2015, CLIN INFECT DIS, V61, P445, DOI 10.1093/cid/civ316eng
hcfmusp.relation.referenceDiaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4eng
hcfmusp.relation.referenceDing X, 2012, JAIDS-J ACQ IMM DEF, V61, P441, DOI 10.1097/QAI.0b013e31826f993ceng
hcfmusp.relation.referenceDrozd DR, 2017, JAIDS-J ACQ IMM DEF, V75, P568, DOI 10.1097/qai.0000000000001450eng
hcfmusp.relation.referenceDuncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008eng
hcfmusp.relation.referenceElion RA, 2018, JAIDS-J ACQ IMM DEF, V78, P62, DOI [10.1097/qai.0000000000001642, 10.1097/QAI.0000000000001642]eng
hcfmusp.relation.referenceFriis-Moller N, 2016, EUR J PREV CARDIOL, V23, P214, DOI 10.1177/2047487315579291eng
hcfmusp.relation.referenceGrangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673eng
hcfmusp.relation.referenceGupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730eng
hcfmusp.relation.referenceLorgis L, 2013, CIRCULATION, V127, P1767, DOI 10.1161/CIRCULATIONAHA.113.001874eng
hcfmusp.relation.referenceMahajan AP, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327438.13291.62eng
hcfmusp.relation.referenceMalta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911eng
hcfmusp.relation.referenceMalta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308eng
hcfmusp.relation.referenceNauta ST, 2012, DIABETES CARE, V35, P2043, DOI 10.2337/dc11-2462eng
hcfmusp.relation.referenceObel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.xeng
hcfmusp.relation.referenceSabin CA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0588-4eng
hcfmusp.relation.referenceSchmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9eng
hcfmusp.relation.referenceSchmidt M, 2016, CIRC-CARDIOVASC QUAL, V9, P523, DOI 10.1161/CIRCOUTCOMES.115.002661eng
hcfmusp.relation.referenceSchmidt M, 2014, NEUROLOGY, V82, P340, DOI 10.1212/WNL.0000000000000062eng
hcfmusp.relation.referenceShah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369eng
hcfmusp.relation.referenceSmolina K, 2012, CIRC-CARDIOVASC QUAL, V5, P532, DOI 10.1161/CIRCOUTCOMES.111.964700eng
hcfmusp.relation.referenceWalker RW, 2013, LANCET GLOB HEALTH, V1, pE282, DOI 10.1016/S2214-109X(13)70068-8eng
hcfmusp.relation.referenceZanni MV, 2012, CURR HIV-AIDS REP, V9, P200, DOI 10.1007/s11904-012-0123-yeng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - LIM/39
LIM/39 - Laboratório de Processamento de Dados Biomédicos

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)239.92 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.